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ABSTRACT
Introduction and Design. The introduction of the epi-
dermal growth factor receptor inhibitors (EGFR-I) has
increased the treatment options available for patients with
metastatic colorectal cancer (mCRC). Two EGFR-I agents
currently approved for the treatment of mCRC are the fully
human monoclonal antibody panitumumab and the mouse-
human chimeric monoclonal antibody cetuximab. While
these agents have demonstrated activity across multiple
lines of therapy, early studies suggested that clinical beneﬁt
was conﬁned to a subset of patients treated. Mutation of the
KRAS oncogene has emerged as a powerful negative pre-
dictive biomarker to identify patients with mCRC who do
not beneﬁt from EGFR-I therapy. Multiple retrospective
analyses have demonstrated that clinical beneﬁt from
treatment with EGFR-I is limited to patients with tumors
harboring the wild-type KRAS gene. In this review, the
KRAS pathway and studies evaluating KRAS as a prog-
nostic marker in CRC are discussed along with advances in
KRAS gene mutation testing. Clinical trials evaluating the
role of KRAS status in response to EGFR-I monotherapy or
in combination with chemotherapy are also highlighted
along with ongoing studies evaluating the role of EGFR-I
treatment on curative resections rates.
Results and Conclusion. Future studies investigating
EGFR-I therapy in mCRC should incorporate KRAS
mutation testing into the study protocol in order to more
accurately determine the patient population that will obtain
clinical beneﬁt from these novel agents.
Colorectalcancer(CRC)remainsthefourthleadingcause
of cancer diagnosis and the second leading cause of cancer-
related deaths in the United States.
1 Treatment of patients
with metastatic colorectal cancer (mCRC) has dramatically
changed over the last decade. A marked advance in the
treatment of patients with mCRC is represented by the
monoclonal antibody epidermal growth factor receptor
inhibitors (EGFR-I), including the fully human monoclonal
antibody panitumumab and the mouse-human chimeric
monoclonal antibody cetuximab. The small molecule
inhibitorsoftheEGFRtyrosinekinasedomain,erlotiniband
geﬁtinib, have demonstrated activity in non-small-cell lung
cancer but have not demonstrated a clinically important
beneﬁt in patients with mCRC.
2,3 Both of the monoclonal
antibody EGFR-I are approved for use in patients with
mCRC as monotherapy, and cetuximab is also approved in
combination with irinotecan.
4,5 Studies with EGFR-I dem-
onstrate that a select group of patients with mCRC exhibit
clinical beneﬁt, with response rates of approximately 10%
observed across several large EGFR-I monotherapy clinical
trials.





who would beneﬁt from EGFR-I is of paramount impor-
tance, and testing of KRAS may help to improve selection of
these patients.
K-ras (OMIM 190070) is a member of the Ras family of
small G proteins involved in intracellular signaling.
11
Activating mutations in KRAS results in the constitutive
activation of downstream signaling pathways and confers
resistance to inhibition of cell surface receptor tyrosine
kinases, including EGFR.
12
Several studies have evaluated the role of KRAS muta-
tion as both a prognostic and predictive marker.
13–27
Prognostic markers provide information on the outcome of
the patient irrespective of the therapeutic intervention,
while predictive markers are speciﬁc to the therapy
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CRC carcinogenesis and was observed in 27–43% of
patients with CRC (Table 1).
13–19 Several older studies
suggest that KRAS mutation is prognostic in CRC
patients.
20,21 However, recent studies continue to question
the prognostic value of KRAS in mCRC.
22,23
Biomarker analysis from several recent studies demon-
strated that patients with KRAS mutated tumors are
resistant to monotherapy with cetuximab or pani-
tumumab.
14,23,24 The additional beneﬁt of EGFR-I to
chemotherapy is limited to patients with wild-type (WT)
KRAS mCRC.
25–27 However, the optimal biologic agent
(bevacizumab or EGFR-I) to be combined with chemo-
therapy for the ﬁrst- or second-line treatment of patients
with WT KRAS mCRC remains to be determined.
Here, we review recent studies involving EGFR-I in
advanced CRC with particular attention to incidence,
prognostic value, and predictive signiﬁcance of the KRAS
mutation in CRC patients.
KRAS MUTATION IN CRC
TheKRASoncogeneencodesthehumancellularhomolog
of the transforming gene Kirsten rat sarcoma-2 virus.
11 The
K-ras protein is a self-inactivating signal transducer. K-ras
cycles between a guanosine diphosphate (GDP) bound
(‘‘off’’ state) to guanosine triphosphate (GTP) bound (‘‘on’’
state) in response to receptor activation. When receptor
tyrosinekinases,suchasEGFR,bindligands(e.g.,epidermal
growth factor, transforming growth factor-a), the receptor
dimerizes and undergoes a conformational change that
results in phosphorylation of tyrosine residues, which leads
toactivationofsignalingpathwaysthatincludetheRas-Raf-
Mek kinase pathway. This response is usually transient as a
result of the intrinsic GTPase activity of K-ras.
12 However,
KRAS activating mutations abolish this intrinsic GTPase
activity, resulting in constitutively active K-ras proteins that
activate downstream signaling pathways and can lead to
oncogenesis (Fig. 1).
12
Activating KRAS mutations are among the most com-
mon oncogenic alterations in cancer, occurring early in
CRC carcinogenesis.
28 In one study, 58% of colonic ade-
nomas of [1 cm carried the KRAS mutation.
29 The
importance of KRAS to colorectal tumorigenesis is under-
scored by the ﬁnding that colon cancer cells in which a
mutated KRAS gene has been removed or replaced lose
their ability to form tumors in mice.
30 The incidence rate of
KRAS mutations is fairly consistent across several studies,
and a similar incidence rate has been reported both in
early-stage and metastatic disease.
21,31–33
TESTING FOR KRAS MUTATIONS
Currently, several methods are used to detect KRAS
mutations within tumors. One method that is generally used
for testing KRAS mutations is an allele-speciﬁc polymerase
chain reaction on DNA from tumor sections, typically
obtained from a formalin-ﬁxed, parafﬁn-embedded block.
This assay uses an allele-speciﬁc primer extension that can
detect the most common KRAS mutations located within
codons 12 and 13 of the gene.
Several commercial assays are available, and currently
there is no standardization. Recently, a comparability study
of four commercially available KRAS tests was presented at
the annual meeting of the American Association for Cancer
Research.
34 This analysis suggested that assays by allele-
speciﬁc polymerase chain reaction or direct sequencing
accurately detected the presence of mutations within the
TABLE 1 Incidence and rate of response of KRAS mutation within selected studies evaluating KRAS as a predictive biomarker to epidermal










Cetuximab ? irinotecan, cetuximab ?
FOLFIRI, cetuximab




48 32 (67%) 16 (33%) 31 6 Benvenuti et al.
14
Cetuximab, cetuximab ? irinotecan 108 66 (61%) 42 (39%) 41 0 De Roock et al.
15
Cetuximab ? irinotecan, cetuximab, cetuximab ?
oxaliplatin
81 49 (60%) 32 (40%) 27 6.3 Finocchiaro et al.
16
Cetuximab ? irinotecan, cetuximab ?
FOLFIRI, cetuximab
89 65 (73%) 24 (27%) 40 0 Lievre et al.
17
Cetuximab 80 50 (62%) 30 (38%) 48
a 10
a Khambata-Ford et al.
18
Panitumumab 62 38 (61%) 24 (39%) 11 0 Freeman et al.
19
WT wild type, RR% response rate, CR complete response, PR partial response, SD stable disease, MT mutant
a Reported as percentage of disease control (CR ? PR ? SD)
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when compared to direct sequencing conducted by an
internal laboratory. However, an assay that used direct
hybridization technology failed to detect the presence of a
mutation with the same accuracy (Table 2).
34 Recently, the
American Society of Clinical Oncology (ASCO) released a
provisional opinion identifying allele-speciﬁc polymerase
chain reaction and direct sequencing as acceptable methods
for testing of KRAS mutations.
35 In addition, a group of
physicians from the European Union have proposed
guidelines for a European Union quality assurance program
to establish consistency in testing practices across Eur-
ope.
36 When testing for the presence of a KRAS mutation
from patient tumor samples, clinicians should ensure the
validity of the assay through the use of control DNA with
known mutation status.
KRAS MUTATION AS A PROGNOSTIC MARKER
Studies evaluating the role of KRAS mutation as a
prognostic marker in patients with CRC have somewhat
conﬂicting results. A study of patients with stage II/III
CRC demonstrated that KRAS mutant tumoral status was
associated with an increase in the rate of recurrence of their
disease (71%) compared to WT (25%).
20 Another study
demonstrated that the prognostic value of KRAS mutation
was limited to patients with stage I/II CRC.
21 Several other
studies have demonstrated data in support of KRAS muta-
tion as a negative prognostic marker, while others have
concluded otherwise.
31,32,37–39
In patients with mCRC, the prognostic value of KRAS
also presents conﬂicting results. Patients with advanced
disease receiving ﬂuorouracil demonstrated no difference in
survival on the basis of KRAS status.
22 In addition, the
NCIC CO.17 trial of patients with chemorefractory mCRC
treated with cetuximab versus best supportive care (BSC)
demonstrated no survival differences among patients with
WT KRAS or mutant tumors receiving BSC.
23 In contrast,
the updated KRAS analysis of the pivotal bevacizumab with
or without chemotherapy (IFL) study demonstrated
lower median overall survival for mutant tumor KRAS
patients versus WT in both treatment arms (IFL:
ABC
FIG. 1 K-ras mutation governs the effects of inhibition of epidermal
growth factor receptor (EGFR) on the Ras/Raf/Mek signaling
pathway. a The ligands epidermal growth factor (EGF) or transform-
ing growth factor (TGF)-a activate EGFR signaling leading to
phosphorylation of the tyrosine kinase domain. K-Ras adopts a
guanosine triphosphate (GTP) bound conformation and through a
series of phosphorelays activates ERK. Activation of ERK leads to
transcription of genes associated with cell proliferation, survival, and
metastasis. b Inhibition of EGFR by the EGFR-I panitumumab or
cetuximab leads to K-ras becoming guanosine diphosphate (GDP)
bound, which inhibits downstream signaling. c When K-ras is
mutated, it adopts a constitutively GTP bound conformation leading
to activation of the Ras/Raf/Mek pathway in the presence of
inhibition of EGFR. Adapted with permission from Khambata-Ford
et al.
18
TABLE 2 Comparison of four commercially available KRAS mutation tests to the expected standard determined by direct sequencing con-










KRAS WT detected/expected 20/21 18/21 3/21 15/21
KRAS mutations detected/expected 20/19 14/19 24/19 20/19
Inconclusive
a 0 8 13 5
PCR polymerase chain reaction, WT wild type
a KRAS tests with inconclusive, failed, or mixed results
1170 A. D. Siddiqui, B. Piperdi17.6 months WT vs. 13.6 months mutant; IFL with
bevacizumab: 27.7 months WT vs. 19.9 months mutant),
although statistical models were not powered to detect the
signiﬁcance of these differences.
40 Therefore, the prognostic
signiﬁcance of KRAS in patients with CRC is still inconclu-
sive.Themostlikelyexplanationforthedisparityintheresults
is the heterogeneity of the patient population. Future studies
should attempt to stratify patient groups by stage of disease,
primary tumor site, and presence of other biomarkers.
KRAS MUTATION PREDICTS RESISTANCE
TO EGFR-I THERAPY
Early small retrospective studies correlated activating
mutation of KRAS with resistance or lack of response to
EGFR-I in patients with mCRC, establishing the proof of
concept for further investigation of this biomarker.
13–19 In
these studies, patients were treated with panitumumab or
cetuximab monotherapy, or cetuximab in combination with
irinotecan or other chemotherapeutic agents (Table 1).
13–19
Mutant KRAS status in these patients was associated with a
lack of response to EGFR-I-based therapy. Most patients
with mutated KRAS tumors did not have an objective
response when treated with EGFR-I-based therapy
(Table 1). Although the role of KRAS mutation as a neg-
ative predictive marker of response to therapy was
demonstrated in these studies, deﬁnitive conclusions could
not be made as a result of the small patient numbers and
differences in treatment.
The ﬁrst large study to analyze the effect of KRAS
mutational status with efﬁcacy with EGFR-I monotherapy
was conducted with patient tumor samples from the pivotal
panitumumab registrational trial.
24 In this randomized
phase 3 trial, patients with chemorefractory mCRC were
randomized to panitumumab or BSC, allowing patients to
cross over from BSC to panitumumab at disease progres-
sion.
8 KRAS status was determined in 427 (92%) of 463
patients (208 panitumumab and 219 BSC) with KRAS
mutations identiﬁed in 184 (43%) of 427 patients (84 [40%]
in the panitumumab arm).
24 In the subset of patients with
WT KRAS tumors, progression-free survival (PFS) was
improved with panitumumab versus BSC treatment
(Table 3). Median PFS time was 2.8 months for pani-
tumumab vs. 1.7 months for BSC in the WT group (hazard
ratio [HR] .45, P\.0001). No beneﬁt was seen regardless
of treatment in patients with mutant KRAS tumors.
Response rates to panitumumab were 17 and 0% for the WT
and mutant groups, respectively. In patients randomized to
BSC who subsequently received panitumumab in the cross
over study, PFS was longer in patients with WT KRAS
tumors (3.8 months WT vs. 1.8 months mutant (HR .32;
95% conﬁdence interval [95% CI] 0.22–0.46). The results
of these analyses demonstrated that response to pani-
tumumab was conﬁned to patients with WT KRAS tumors.
24
Similar ﬁndings have been demonstrated in a large
randomized phase 3 trial of patients treated with cetuximab
monotherapy.
23 In this study, 572 patients with chemore-
fractory mCRC were randomized to cetuximab versus
BSC. The crossover of BSC patients to the cetuximab arm
of the trial was not mandated by the study protocol.
7 Tumor
specimens were available for KRAS mutational testing
from 394 patients (69%) with mutations detected in 42% of
these patients. Among patients treated with cetuximab, the
objective response rate for WT KRAS patients was 12.8%,
compared with a 1.2% response rate for patients in the
KRAS mutant group. Cetuximab monotherapy was associ-
ated with signiﬁcant improvements in PFS (3.7 vs.
1.9 months, P\.001) and overall survival in WT KRAS
patients treated with cetuximab (9.5 months for cetuximab
vs. 4.8 months for BSC, P\.001) (Table 3). However,
increased overall survival was not observed in patients with
KRAS-mutated tumors (4.5 months for cetuximab vs.
4.6 months for BSC, P = .89).
The data from these studies strongly support the
hypothesis that the activating mutation in KRAS confers
resistance to EGFR-I. The clinical beneﬁt from single-
TABLE 3 Response rate and progression-free survival of patients treated in phase 3 epidermal growth factor receptor inhibitor monotherapy
trials by KRAS mutational status
23,24
KRAS Panitumumab BSC HR (P) Cetuximab BSC HR (P)
WT KRAS
Response rate 17% 0% 12.8% 0%
Median PFS 2.8 mo
a 1.7 mo
a .45 (\.0001) 3.7 mo 1.9 mo .40 (\.001)
Mutant KRAS
Response rate 0% 0% 1.2% 0%
Median PFS 1.7 mo
a 1.7 mo
a .99 (NR) 1.8 mo 1.8 mo .99 (.96)
NR not reported, PFS progression free survival, BSC best supportive care, HR hazard ratio for progression-free survival
a Reported as weeks in the original publication
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with WT KRAS. In WT KRAS patients, EGFR-I treatment
is associated with marked objective response, and
improvements in PFS and overall survival over BSC in
patients with chemorefractory mCRC.
BENEFIT FROM THE ADDITION OF EGFR-I
TO CHEMOTHERAPY IS LIMITED
TO WT KRAS PATIENTS
Several recent studies have evaluated the addition of
cetuximab or panitumumab to standard chemotherapy in
ﬁrst- or second-line setting in patients with mCRC. Data
from these studies have demonstrated an association
between KRAS mutational status and response to the
addition of EGFR-I to standard chemotherapy.
Two studies presented at the 2009 ASCO annual meet-
ing examined the safety and efﬁcacy of panitumumab in
combination with irinotecan-based chemotherapy in
patients with mCRC whose disease previously failed to
respond to oxaliplatin-based therapy. In the PRECEPT
trial, the role of KRAS is being prospectively evaluated in
patients with mCRC treated with panitumumab with
FOLFIRI; the STEPP study also evaluated the efﬁcacy of
panitumumab in combination with FOLFIRI or irinotecan
with KRAS mutational status available for 92% of
patients.
25,41 In both of these studies, clinical end points for
efﬁcacy of panitumumab with chemotherapy were in favor
of patients with WT KRAS tumors.
25,41
A more favorable efﬁcacy proﬁle was reported among
patients with WT KRAS mCRC receiving cetuximab in
combination with FOLFOX in a randomized phase 2 trial
evaluating FOLFOX with or without cetuximab as ﬁrst-line
treatment (OPUS).
26 Efﬁcacy results of the WT KRAS
population demonstrated that response rate greatly
increased when cetuximab was added to FOLFOX (61 vs.
37%, P = .011). Conversely, patients with mutant KRAS
had a nonsigniﬁcant decrease in response rate when ce-
tuximab was added to FOLFOX (33 vs. 49%, P = .106).
These data suggest that clinical beneﬁt from addition of
cetuximab to FOLFOX is limited to patients with WT
KRAS.
In the CRYSTAL trial, previously untreated patients
with mCRC were randomized to FOLFIRI with or without
cetuximab.
27 Of the 1198 patients analyzed in the original
intention-to-treat population, 540 (45%) were included in
the KRAS analysis and 36% had a KRAS mutation. The
addition of cetuximab to FOLFIRI in patients with WT
KRAS tumors resulted in a nonsigniﬁcant increase in
median PFS compared to patients receiving FOLFIRI alone
(9.9 vs. 8.7 months, P = .07). In contrast, the median PFS
of mutant tumor KRAS patients receiving cetuximab with
FOLFIRI was lower (7.6 months) compared with patients
receiving FOLFIRI alone (8.1 months, HR 1.07, 95% CI
0.71–1.61). A nonsigniﬁcant increase in overall survival
was observed in WT KRAS patients treated with cetuximab
with FOLFIRI compared to patients treated with FOLFIRI
alone (24.9 vs. 21 months, P = .44).
27 These data dem-
onstrate that the beneﬁt observed from the addition of
cetuximab to chemotherapy is limited to patients with WT
KRAS tumors; however, future studies will be needed to
determine the optimal clinical settings for the use of ce-
tuximab in combination with FOLFIRI in the ﬁrst-line
treatment of mCRC.
An important ﬁnding from the CRYSTAL trial was the
observation that the surgical resection rate of metastases
was higher in patients treated with cetuximab with
FOLFIRI compared to patients treated with FOLFIRI alone
(7.0 vs. 3.7%).
27 In addition, the R0 resection rate with
curative intent was statistically higher in favor of patients
receiving cetuximab (4.8 vs. 1.7%; odds ratio for cetux-
imab with FOLFIRI group, 3.02; 95% CI, 1.45–6.27;
P = .002).
27 However, the relationship of these ﬁndings
from the CRYSTAL trial to KRAS status of the tumor is
currently unknown.
Recently, at the 2009 Gastrointestinal Cancers Sympo-
sium, Folprecht et al. presented preliminary data from a
randomized multicenter study of cetuximab with FOLFOX
or FOLFIRI in neoadjuvant treatment of nonresectable
colorectal liver metastasis (CELIM study).
42 A conﬁrmed
overall response rate of 70% was observed in patients with
WT KRAS tumors treated with FOLFOX or FOLFIRI with
cetuximab.
42 Among all patients with disease that was
initially deemed nonresectable, 25% were classiﬁed as
resectable after treatment. Overall, 34% of patients enrol-
led onto the CELIM study underwent R0 resection and
demonstrated no evidence of residual disease.
42 Perioper-
ative morbidity and mortality were comparable to historical
data. These preliminary data are encouraging and warrant
further studies of evaluating EGFR-I in combination with
chemotherapy as a neoadjuvant therapy in patients with
KRAS WT tumors with liver metastasis.
Two current phase 3 studies are evaluating the inﬂuence
of KRAS on response to panitumumab with chemotherapy
in patients with mCRC. The PRIME study is evaluating
FOLFOX with or without panitumumab in the ﬁrst-line
setting, while the 20050181 study is evaluating FOLFIRI
with or without panitumumab for second-line treat-
ment.
43,44 Tumor sample availability was required for
enrollment onto these studies, and KRAS status will be
incorporated into the primary analysis to test the role of
KRAS in the combination therapy setting. Future trials
seeking to evaluate the role of a biomarker such as KRAS
may beneﬁt from the incorporation of biomarker evaluation
into the study design.
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The studies mentioned above support the beneﬁcial
effect of the addition of EGFR-I to standard chemotherapy
in patients with WT KRAS mCRC. However, the optimal
biologics to combine with chemotherapy in ﬁrst- and sec-
ond-line setting remains unclear.
Retrospective analysis of the pivotal trial of bev-
acizumab with IFL demonstrated no statistically signiﬁcant
correlation between KRAS mutation and the beneﬁt from
bevacizumab.
40 The median PFS for chemotherapy alone
versus chemotherapy with bevacizumab was 7.4 vs.
13.5 months (HR .44; P\.0001) in WT KRAS and 5.5 and
9.3 months (HR .41; P\.0008) in KRAS mutant groups.
Two recent trials have evaluated the safety and efﬁcacy
of the addition of EGFR-I to standard chemotherapy and
bevacizumab in treatment-naive patients with mCRC. The
ﬁrst study to evaluate this combination was the PACCE
trial.
45 In this phase 3 study, patients were randomized to
receive chemotherapy and bevacizumab with or without
panitumumab. The chemotherapeutic regimen was either
FOLFOX or FOLFIRI, based on the choice of the inves-
tigator. Efﬁcacy results demonstrated that patients with WT
or mutant KRAS tumors experienced a decrease in PFS
when panitumumab was added to FOLFOX with bev-
acizumab versus FOLFOX with bevacizumab alone
(Table 4). Similar results were demonstrated in patients
treated in the FOLFIRI cohort (Table 4).
45
The CAIRO2 trial evaluated the combination of cape-
citabine, oxaliplatin, and bevacizumab, with or without
cetuximab.
46 For the total patient group, the addition of
cetuximab was associated with a statistically signiﬁcant
decrease in median PFS and increased grade 3/4 adverse
events. In patients with WT KRAS, there was no statisti-
cally signiﬁcant change in median PFS by the addition of
cetuximab (10.6 vs. 10.5 months, P = .3) (Table 4).
However, patients with mutant KRAS tumors treated with
cetuximab with chemotherapy and bevacizumab had a
statistically signiﬁcant decrease in median PFS compared
to mutant tumor KRAS patients not treated with a cetux-
imab-containing regimen (12.5 vs. 8.1 months, P = .003)
(Table 4). The results of the PACCE and CAIRO2 studies
demonstrate that the addition of EGFR-I to chemotherapy
and bevacizumab for ﬁrst line treatment of mCRC does not
improve clinical outcomes for patients with mCRC,
regardless of KRAS mutational status, and may decrease
clinical outcome. Furthermore, these data strongly suggest
a class effect of EGFR-I when used in combination with
bevacizumab and ﬂuoropyrimidine-based chemotherapy.
Two ongoing studies will continue to evaluate the
optimal biologics to combine with chemotherapy in
patients with WT KRAS mCRC. In the CALGB 80405
study, patients will be randomized to chemotherapy with
bevacizumab alone or cetuximab alone, or in combination
in the ﬁrst-line setting.
47 This study has been amended to
include only patients with WT KRAS tumors. In the phase 2
SPIRITT study, patients with WT KRAS mCRC whose
TABLE 4 Median progression-free survival of patients treated in trials evaluating the addition of epidermal growth factor receptor inhibitor
therapy to ﬂuoropyrimidine-based regimens in combination with bevacizumab
KRAS PACCE oxaliplatin cohort
a
FOLFOX ? bevacizumab (months) Panitumumab ? FOLFOX ? bevacizumab (months) HR (95% CI)
WT KRAS 11.5 9.8 1.36 (1.04–1.77)
KRAS MT 11.0 10.4 1.25 (0.91–1.71)
KRAS PACCE irinotecan cohort
a
FOLFIRI ? bevacizumab (months) Panitumumab ? FOLFIRI ? bevacizumab (months) HR (95% CI)
WT KRAS 12.5 10.0 1.50 (0.82–2.76)
KRAS MT 11.9 8.3 1.19 (0.65–2.21)
KRAS CAIRO2
b
CAPEOX ? bevacizumab (months) Cetuximab ? CAPEOX ? bevacizumab (months) P value
WT KRAS 10.6 10.5 .30
KRAS MT 12.5 8.1 .003
WT wild type, HR hazard ratio for progression-free survival, 95% CI 95% conﬁdence interval, MT mutant
a Hecht et al.
45
b Tol et al.
46
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motherapy and bevacizumab will be randomized to
FOLFIRI with either bevacizumab or panitumumab.
48
These studies will provide further information about the
optimal biologic to combine with standard chemotherapy
in patients with WT KRAS mCRC.
FUTURE DIRECTIONS IN BIOMARKER
RESEARCH TO EGFR-I-BASED THERAPY
Mutation of the KRAS gene has emerged as a powerful
biomarker of resistance to EGFR-I-based therapy.
Although most studies focus on mutations within codons
12 and 13 of the KRAS gene, a recent analysis demon-
strated that mutations within codons 61 and 146 also
confer resistance to EGFR-based therapy.
49 Recent studies
have demonstrated that in addition to KRAS, other bio-
markers including BRAF (OMIM 164757) and PIK3CA
(OMIM 171834) can increase the predictive ability of
response to EGFR-I in patients with WT KRAS tumoral
status.
49–51 However, data from another study suggest that
PIK3CA does not predict for response to EGFR-I therapy,
and further studies will be needed to validate PIK3CA as
a predictive biomarker.
52 In addition, a retrospective
analysis suggested that patients treated on the NCIC
CO.17 clinical trial with WT KRAS tumors and high
mRNA expression of the EGFR ligand epiregulin (OMIM
602061) may derive the greatest beneﬁt from cetuximab
therapy.
53 Continued evaluation of these biomarkers and
others will allow for a personalized approach for the
treatment of patients with mCRC.
CONCLUSIONS
The desired goal in cancer therapy is to individualize
treatment according to the underlying predictive factors to
minimize the unnecessary adverse effects and complica-
tions from cancer treatment. Recent data on the presence of
a KRAS mutation and lack of response to EGFR-I represent
an important step toward achieving that goal. Great pro-
gress has been made in the treatment of patients with
mCRC over the last 10 years. The availability of newer
chemotherapy and biologics has increased treatment
options for patients and clinicians.
The current data strongly support the hypothesis that
patients with KRAS mutation with mCRC have disease
resistant to EGFR-I therapy. The beneﬁcial effects of
EGFR-I monotherapy or in combination with chemother-
apy are limited to patients with WT KRAS tumors.
Preliminary data suggest that EGFR-I in combination with
chemotherapy can result in improvements in tumor
responses and can potentially lead to downstaging of
patients with nonresectable KRAS WT liver metastases.
Testing for KRAS mutation should be strongly considered
in patients with mCRC before the initiation of any EGFR-I.
The current data do not support the addition of anti-EGFR
monoclonal antibodies to standard chemotherapy with
bevacizumab in the ﬁrst-line setting. Ongoing trials will
address the optimal biologics to combine with chemo-
therapy in WT KRAS patients.
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NOTE ADDED IN PROOF During the review of this paper, the
results of the PRIME and 20050181 phase 3 clinical trials discussed
above were presented at the 2009 Joint ECCO 15—ESMO 34th
Multidisciplinary Congress in Berlin, Germany. The results of both of
these studies demonstrated signiﬁcant increases in median PFS of
patients with WT KRAS mCRC who received chemotherapy with
panitumumab compared with patients receiving chemotherapy alone.
(Peeters M, et al. European Journal of Cancer Supplements, Vol. 7,
No 3, September 2009, Page 9, Abstract 14LBA; Douillard J, et al.
European Journal of Cancer Supplements, Vol. 7, No 3, September
2009, Page 6, Abstract 10LBA) A similar beneﬁt to panitumumab was
not observed in patients with KRAS mutant tumors. These data
provide further support to the conclusions made in this manuscript.
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